US-based biotechnology firm Moderna has partnered with European pharmaceutical company Laboratorios Farmacéuticos Rovi (ROVI) for finish-fill manufacturing of its Covid-19 vaccine candidate, mRNA-1273.
Moderna’s vaccine was among the first to be tested in humans in the United States and was found to produce protective antibodies in a small group of healthy volunteers in May.